-
1 Comment
Mochida Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 8.0% below its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Mochida Pharmaceutical Co., Ltd's total revenue rose by 2.4% to $28B since the same quarter in the previous year.
Its net income has increased by 67.7% to $3B since the same quarter in the previous year.
Based on the above factors, Mochida Pharmaceutical Co., Ltd gets an overall score of 3/5.
| CurrencyCode | JPY |
|---|---|
| ISIN | JP3922800002 |
| Exchange | TSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | 20.16 |
|---|---|
| Market Cap | 115B |
| Target Price | None |
| Beta | 0.0 |
| Dividend Yield | 0.0% |
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4534.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
